Zenas BioPharma Inc (ZBIO)

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the...

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results...

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE...

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D...

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq:...

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this...

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq:...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses